Economics of gastroenteropancreatic neuroendocrine tumors: a systematic review
Autor/a
Grande, Enrique
Díaz, Ángel
López, Carlos
Munarriz, Javier
Reina, José Juan
Vera, Ruth
Bernardez, Beatriz
Aller, Javier
Capdevila, Jaume
García Carbonero, Rocío
Jimenez-Fonseca, Paula
Trapero-Bertran, Marta
Data de publicació
2019-02-18ISSN
2042-0188
Resum
Background:
Despite current interest, enthusiasm and progress in the development of therapies for gastroenteropancreatic (GEP) neuroendocrine tumors (NETs), there are substantial gaps in the published literature regarding cost-of-illness analyses, economic evaluation and budget impact analyses. Compounding the issue is that data on resource utilization and cost-effectiveness of different diagnostic and therapeutic modalities for GEP-NETs are scarce.
Methods:
A systematic review on the economic impact of GEP-NETs was carried out using four databases: EMBASE, PubMed, the National Health Service Economic Evaluation Database and Cochrane review. Fully published articles from January 2000 to May 2017, in English and Spanish, were included. All articles that satisfied the inclusion criteria were included in the systematic review; summary descriptive statistics were used to describe the methodological characteristics.
Results:
The 14 studies selected included cost-of-illness analyses (n = 4), economic evaluations (n = 7) and budget impact analyses (n = 3). Almost all studies were performed in the United States. Healthcare costs for patients with NETs included medication, outpatient visits, hospitalizations, and check-ups/tests. Reducing adverse events is an area where cost savings could be achieved; however, there was not enough evidence on the cost impact of adverse events.
Conclusion:
There is a lack of data related to resource utilization in the field of GEP-NETs. Therefore, cost-effectiveness and budget impact studies of existing and emerging treatments are urgently needed to help the decision-making process for patients with NETs.
Tipus de document
Article
Versió del document
Versió acceptada
Llengua
English
Matèries (CDU)
338 - Situació econòmica. Política econòmica. Gestió, control i planificació de l'economia. Producció. Serveis. Turisme. Preus
61 - Medicina
Paraules clau
Cost effectiveness
Cost-eficàcia
Costes
Gestió pressupostària
Budget in business
Control presupuestario
Serveis sanitaris
Servicios de salud
Health facilities
Pàgines
12
Publicat per
SAGE Publications
Col·lecció
10;
Publicat a
Therapeutic Advances in Endocrinology and Metabolism
Citació
Grande, Enrique; Díaz, Ángel; López, Carlos et al. «Economics of gastroenteropancreatic neuroendocrine tumors: a systematic review». Therapeutic Advances in Endocrinology and Metabolism, 2019, vol 10. Disponible en: <http://journals.sagepub.com/doi/10.1177/2042018819828217>. Fecha de acceso: 21 ene. 2020. DOI: 10.1177/2042018819828217
Aquest element apareix en la col·lecció o col·leccions següent(s)
Drets
http://creativecommons.org/licenses/by-nc-nd/4.0/
Excepte que s'indiqui una altra cosa, la llicència de l'ítem es descriu com http://creativecommons.org/licenses/by-nc-nd/4.0/